InMed Pharmaceuticals Inc. has announced the presentation of new preclinical data from its INM-901 program at the Alzheimer's Association International Conference $(AAIC)$ 2025. The study focuses on INM-901, a proprietary small molecule drug candidate targeting multiple biological pathways in Alzheimer's disease. The research highlights long-term treatment results in an advanced 5xFAD mouse model, demonstrating improvements in cognitive function, anxiety-related behavior, and sensory responsiveness. Key findings include INM-901's anti-inflammatory action, neuroprotective effects, and promotion of neuronal regeneration. The presentation is scheduled for the conference taking place from July 27-31, 2025, in Toronto, Canada, with a scientific poster detailing the study results. The data will be made available on InMed's website following the event.